Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients: Geriatric Screening in Action

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on older adults with ER+/HER2- early-stage breast cancer who are starting adjuvant CDK4/6 inhibitors with endocrine therapy. It aims to examine how geriatric screening relates to treatment choices, toxicity, quality of life, and need for dose modifications or discontinuation. The study will collect data on hospitalizations, recurrence, survival, and treatment intensity in routine clinical practice. Researchers will explore associations between geriatric assessment results and clinical outcomes to inform individualized treatment decisions. The findings may guide integration of geriatric screening into standard care for this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥70 years old
* Female/male
* Completed surgery (primary or after neoadjuvant therapy)
* Starting adjuvant CDK4/6i and endocrine therapy
* Cognitive performance to be able answer questionaries
* No language difficulties

Exclusion Criteria:

* Impaired cognitive function not able to understand the study intention or perform questionaries
* Declining adjuvant CDK4/6i

Where it's running

• Department of Oncology
  Gävle, Sweden Recruiting
• Department of Oncology
  Jönköping, Sweden Recruiting
• Department of Oncology
  Kalmar, Sweden Recruiting
• Department of Oncology
  Linköping, Sweden Recruiting
• Department of Oncology
  Örebro, Sweden Not yet recruiting

Study contacts

• Study coordinator: Christine Lundgren, MD
• Email: christine.lundgren@rjl.se
• Phone: +46102422907

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Regular exercise to help women with early-stage breast cancer on hormone therapy

  This study tests whether a guided, 16-week exercise program improves quality of life and fitness for women with early-stage breast cancer who are starting adjuvant hormone therapy.

  Recruiting Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares · San Sebastián de los Reyes, Madrid · NCT07893327

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Personalised Tamoxifen Dose to Improve Treatment in Early-Stage Breast Cancer

  This trial tests whether adjusting tamoxifen doses based on how each patient metabolizes the drug can improve outcomes for women with early-stage hormone receptor–positive breast cancer.

  Recruiting at 2 sites Phase 3 Karolinska Institutet · Borås and 3 other locations · NCT07502820

• Time‑restricted eating (8‑hour window) during chemotherapy for breast cancer: feasibility and acceptability

  This trial will test whether eating all daily food within an 8‑hour window is practical and acceptable for people starting chemotherapy for stage I–III breast cancer (and some stage IV with oncologist approval).

  Recruiting at 2 sites University of Illinois Chicago · Chicago, Illinois and 1 other locations · NCT07387445

• CPAP-assisted radiotherapy to lower heart and lung dose after breast-conserving surgery

  This tests whether wearing a CPAP breathing device during adjuvant radiotherapy can lower radiation exposure to the heart and lungs for women with early-stage (stage 1–3) breast cancer who had breast‑conserving surgery.

  Recruiting Phase 2/3 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07373782

• Oncoliq blood test for early detection of breast cancer

  This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.

  Recruiting Oncoliq US Inc · Buenos Aires, Buenos Aires · NCT07331506

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.